LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
Another mixed quarter in Q3 FY'22 for AngioDynamics, despite strengths in its international markets. Management revised guidance higher, but this may widen the operating loss as well, in my view.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results